About Acerta Pharma
Acerta Pharma is a company based in Oss (Netherlands) founded in 2012 was acquired by Astrazeneca in December 2015. It operates as a Professional Services. Acerta Pharma has raised $13 million across 1 funding round from investors including Astrazeneca, Orbimed and Frazier Healthcare Partners. Acerta Pharma offers products and services including Haematology Medicines. Acerta Pharma operates in a competitive market with competitors including Adicet Bio, Orca Bio, Ossium Health, Auron Therapeutics and Nordic Nanovector, among others.
- Headquarter Oss, Netherlands
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Acerta Pharma B.V.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$13 M (USD)
in 1 rounds
-
Latest Funding Round
$13 M (USD), Series B
Dec 31, 2013
-
Investors
Astrazeneca
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Astrazeneca
(Dec 17, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Acerta Pharma
Acerta Pharma offers a comprehensive portfolio of products and services, including Haematology Medicines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medicines are developed for hematological malignancy treatments.
Unlock access to complete
Unlock access to complete
Funding Insights of Acerta Pharma
Acerta Pharma has successfully raised a total of $13M through 1 strategic funding round. The most recent funding activity was a Series B round of $13 million completed in December 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $13.0M
-
First Round
First Round
(31 Dec 2013)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2013 | Amount | Series B - Acerta Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Acerta Pharma
Acerta Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, Orbimed and Frazier Healthcare Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Pharmaceutical and biologics products are developed and distributed worldwide.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Acerta Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Acerta Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acerta Pharma Comparisons
Competitors of Acerta Pharma
Acerta Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, Orca Bio, Ossium Health, Auron Therapeutics and Nordic Nanovector, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immune cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| domain | founded_year | HQ Location |
Ossium Health is focused on bioengineering for improved health.
|
|
| domain | founded_year | HQ Location |
Developer of cancer therapeutics for the treatment of blood cancer
|
|
| domain | founded_year | HQ Location |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| domain | founded_year | HQ Location |
Monoclonal antibody therapies for pediatric leukemia are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acerta Pharma
Frequently Asked Questions about Acerta Pharma
When was Acerta Pharma founded?
Acerta Pharma was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Where is Acerta Pharma located?
Acerta Pharma is headquartered in Oss, Netherlands. It is registered at Oss, Noord-brabant, Netherlands.
Is Acerta Pharma a funded company?
Acerta Pharma is a funded company, having raised a total of $13M across 1 funding round to date. The company's 1st funding round was a Series B of $13M, raised on Dec 31, 2013.
What does Acerta Pharma do?
Acerta Pharma, an affiliate of AstraZeneca, is engaged in advancing scientific research to redefine care in haematology. Novel investigational agents are developed to target cancer cells directly or harness the immune system for cancer elimination. The focus is placed on addressing blood cancers with high unmet needs through an innovative pipeline. Collaboration with AstraZeneca enables the combination of extensive oncology portfolios for enhanced cancer therapies. Research and development activities are conducted at the Oss site in the Netherlands, emphasizing target identification and compound optimization.
Who are the top competitors of Acerta Pharma?
Acerta Pharma's top competitors include Orca Bio, Ossium Health and Adicet Bio.
What products or services does Acerta Pharma offer?
Acerta Pharma offers Haematology Medicines.
Who are Acerta Pharma's investors?
Acerta Pharma has 3 investors. Key investors include Astrazeneca, Orbimed, and Frazier Healthcare Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.